RAD54L2 and gastrointestinal stromal tumor: RAD54L2 was associated with poor clinical outcomes in gastrointestinal stromal tumors (Schoppmann et al, 2013) and in a pediatric AML cohort treated with etoposide (Nguyen et al, 2023).